ISAR-LEFT MAIN 2 Trial: Zotarolimus- versus Everolimus- Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions

Article Information

DOI 
http://dx.doi.org/10.1177/155989771217009
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2012 MD Conference Express®

Author Information

  1. Toni Rizzo
  1. Julinda Mehilli, MD
    1. German Heart Centre Munich, Munich, Germany
View Full Text

Article usage

AbstractFullPDF
Apr 2015600
May 2015200
Jul 2015111
Aug 2015100
Sep 2015100
Oct 2015233
Nov 2015200
Total1544

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
ISAR-LEFT MAIN 2 Trial: Zotarolimus- versus Everolimus- Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Interventional Techniques & Devices
Valvular Disease
Cardiology Clinical Trials